DAVITA INC.

DaVita Inc. has a capital structure marked by a high debt load, with long-term debt of $10.16 billion and total liabilities of $16.32 billion, compared to total assets of $17.48 billion. The company's liquidity position is moderate, with cash and equivalents of $676.4 million and a current ratio of 1.29. However, the company's total equity is negative at -$651.1 million, and the debt-to-equity ratio is -15.61, indicating a significant reliance on debt financing. Profitability metrics show mixed results. The company reported an operating income of $2.04 billion and a net income of $746.8 million for FY2025. However, the return on equity is negative at -1.147, while the return on assets is 0.0427. These figures suggest that the company is generating returns on its assets but is not effectively leveraging equity to generate returns for shareholders. DaVita's revenue is primarily concentrated in the United States, where it operates dialysis centers and provides integrated kidney care services. The company also has international operations, though the exact revenue contribution from these is not specified. The company's business is heavily influenced by the prevalence of chronic kidney disease and end-stage kidney disease, which are driven by factors such as diabetes and hypertension. The company's growth trajectory is influenced by both internal and external factors. The FY2025 outlook indicates a focus on maintaining and expanding its integrated care arrangements. However, the company faces challenges from potential changes in demand due to new treatments and technologies, such as GLP-1 receptor agonists and SGLT2 inhibitors. Additionally, the company's capital expenditure of $575.9 million reflects ongoing investments in infrastructure and services. Risk factors for DaVita include regulatory changes, the potential for dilution, and the impact of new medical technologies. The company's diluted share count is significantly higher than the basic share count, indicating a high dilution risk. The risk assessment also notes that the company's net cash is negative after subtracting total debt, which could affect its financial flexibility. The company's exposure to regulatory changes is further compounded by the evolving priorities of various legislative and regulatory bodies. Recent events and filings highlight the company's ongoing monitoring of regulatory updates and enforcement actions. The company has issued new senior notes and performed annual impairment assessments, with no impairment indicated as of September 30, 2025. The company is also tracking the impact of the 2019 Executive Order and related HHS guidance, which aims to increase the number of new ESKD patients receiving dialysis at home.